Physician profile
Thomas C Padgett
NPI 1790868214
$719.62
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $103 · 2021: $220 · 2022: $245.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $185.55 | 2020-2022 | |
| Corium, LLC | $129.73 | 2022 | |
| Supernus Pharmaceuticals, INC. | $61.11 | 2021-2022 | |
| Seqirus USA INC | $51.30 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $46.43 | 2019-2020 | |
| Sobi, INC | $42.50 | 2019 | |
| Sanofi Pasteur INC. | $40.50 | 2020-2021 | |
| Abbvie INC. | $38.61 | 2021-2022 | |
| Glaxosmithkline, LLC. | $32.67 | 2020 | |
| Pfizer INC. | $26.38 | 2019-2022 | |
| Shire North American Group INC | $20.64 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $20.02 | 2019 | |
| Cranial Technologies, INC | $12.79 | 2019 | |
| Merck Sharp & Dohme LLC | $11.39 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Padgett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.